drugset / Trial / NCT00669734
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy directly into the tumor together with sargramostim may cause a stronger immune response and kill more tumor cells.
Timeline
- Start
- 2010-02-01
- Primary completion
- 2021-09-02
- Completion
- 2027-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Falimarev | Vaccine | — | Intrathecal |
| Subject | Inalimarev | Vaccine | — | Subcutaneous |
| Background | sargramostim | Protein / enzyme biologic | — | Subcutaneous |